Pliant Therapeutics beruft David Raben als Chief Medical Officer in Geschäftsleitung

• Pliant Therapeutics hat David Raben zum Chief Medical Officer ernannt.
• Zuletzt Chief Medical Officer bei Bicara Therapeutics; verantwortete die klinische Entwicklung von ficerafusp alfa (BCA101).
• Zuvor bei Amgen als Vice President Global Product Development und Product General Manager Oncology; leitete das Anti-DLL3-Programm.
• Davor Vice President und Franchise Leader Oncology Clinical Development bei Genentech; steuerte späte Präzisionsmedizin- und Immuntherapieprogramme.
• Board-zertifizierter Strahlenonkologe; über 20 Jahre Professor am University of Colorado Cancer Center mit translationaler Onkologie-Forschung.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301610PRIMZONEFULLFEED9837266) on September 30, 2026, and is solely responsible for the information contained therein.